New allergy pill aims to clear stuffy noses in asthma patients
NCT ID NCT07168473
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests two versions of an experimental allergy drug, DW1807 and DW1807-R2, in 274 adults who have year-round allergic rhinitis (hay fever) and asthma. Participants take one pill daily for 4 weeks. The main goal is to see which version better reduces nasal symptoms like stuffiness and sneezing. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERENNIAL ALLERGIC RHINITIS ACCOMPANIED BY ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Konkuk University Medical Center
RECRUITINGSeoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DW1807 (an experimental drug for allergic rhinitis)
What this could lead to
If DW1807 works better than DW1807-R2, it could offer a new treatment option for people with both year-round allergies and asthma, easing nasal symptoms.
What could go wrong
This is a phase 3 trial, but it only lasts 4 weeks and measures symptom scores, not long-term outcomes. The drug may not prove superior or could have side effects not yet seen.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.